Summary: Genmab initiates research cooperation with the Danish DAHANCA-group.
Copenhagen, Denmark; March 16, 2007 - Genmab A/S (CSE: GEN) announced today
that Genmab initiates research cooperation with the Danish Head and Neck Cancer
Group (DAHANCA). Under the cooperation Genmab will supply the fully human
antibody HuMax-EGFr(TM) (zalutumumab) to a Phase III front line study of
approximately 600 Head and Neck cancer patients run by the DAHANCA-group. The
study will be financed by the DAHANCA-group, who is also responsible for
negotiating the study protocol with authorities. Following finalization of the
study protocol the DAHANCA-group will be responsible for running the study and
subsequent publication of results. Genmab has all the rights to regulatory use
of both safety and efficacy data from the study. Further details of the study
are under negotiations by the DAHANCA-group.
About Genmab A/S
Genmab A/S is a biotechnology company that creates and develops human
antibodies for the treatment of life-threatening and debilitating diseases.
Genmab has numerous products in development to treat cancer, infectious
disease, rheumatoid arthritis and other inflammatory conditions, and intends to
continue assembling a broad portfolio of new therapeutic products. At present,
Genmab has multiple partnerships to gain access to disease targets and develop
novel human antibodies including agreements with Roche and Amgen. A broad
alliance provides Genmab with access to Medarex, Inc.'s array of proprietary
technologies, including the UltiMAb(R) platform for the rapid creation and
development of human antibodies to virtually any disease target. In addition,
Genmab has developed UniBody(TM), a new proprietary technology that creates a
stable, smaller antibody format. Genmab has operations in Europe and the US.
For more information about Genmab, visit www.genmab.com.
This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product
discovery and development, uncertainties related to the outcome and conduct of
clinical trials including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our products, our
inability to manage growth, the competitive environment in relation to our
business area and markets, our inability to attract and retain suitably
qualified personnel, the unenforceability or lack of protection of our patents
and proprietary rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and other
factors. Genmab is not under an obligation to up-date statements regarding the
future following the publication of this release; nor to confirm such
statements in relation to actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-EGFr(TM);
HuMax-Inflam(TM); HuMax-CD20(TM); HuMax-TAC(TM); HuMax-HepC(TM),
HuMax-CD38(TM); HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab
A/S.
UltiMAb(R) is a trademark of Medarex, Inc.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M:
+45 25 27 47 13, E: hth@genmab.com
Stock Exchange Release no. 11/2007
